[Elsevier] Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial

Biafer Post time Yesterday 23:31 | Show all posts |Read mode
This post will be closed automatically in 2026-10-04 23:31
Reward10points

journalㄩEuropean Journal of Cancer

AuthorsㄩAna Oaknin; Bradley J. Monk; Andreia Cristina de Melo; Hee Seung Kim; Yong Man Kim; Alla S. Lisyanskaya; Vanessa Samoulian; Domenica Lorusso; Fernanda Damian; Chih-Long Chang; Evgeniy Gotovkin; Shunji Takahashi; Daniella Ramone; Beata Makowiak-Matejczyk; Laura Polastro; Eva Maria Guerra Alia; Nicoletta Colombo; Yulia Makarova; Jeffrey C. Goh; Kosei Hasegawa; Paulo Mora; Joanna Pikiel; Ratnesh Srivastav; Danny Rischin; Maria Jes迆s Rubio; Javier Perez; Suk Young Yoo; Bo Gao; Shaheda Jamil; Frank Seebach; Israel Lowy; Melissa Mathias; Matthew G. Fury; Krishnansu S. Tewari

Published dateㄩ2025-2-

DOIㄩ10.1016/j.ejca.2024.115146

PDF linkㄩhttps://www.sciencedirect.com/sc ... 959804924017532/pdf

Article linkㄩhttps://doi.org/10.1016/j.ejca.2024.115146

Article SourceㄩElsevier BV﹝


Remarkㄩ
Reply

Use magic Donate Report

All Reply1 Show all posts
greg122122 Post time Yesterday 23:59 | Show all posts

Waiting for confirmation

If the PDF has not been accepted after 72 hours, the system will automatically adopt it.
Reply

Use magic Donate Report

Intermediate member
  • post

  • reply

  • points

    420

Return to the list